Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal ...

Iovance Biotherapeutics has hired Corleen Roche as the biotechnology company's new chief financial officer, effective Aug. 6. Iovance on Tuesday said Roche, 59 years old, most recently served as ...

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for ...

Tandem Diabetes Care, Inc. (NASDAQ:TNDM) has agreed to pay Roche $36 million to resolve a patent infringement lawsuit over Tandem’s t:slim X2 insulin pump. The deal settles all pending and ...

A group of advisers to the Food and Drug Administration said Roche Holding AG needs to study its blood cancer treatment in more American patients before its use can be expanded.

Roche announces new Genentech plant in Holly Springs, North Carolina as Wake County town adds jobs from another biopharma giant to list of Fujifilm, Amgen, CSL Seqirus ...

Roche will invest $550 million in Indianapolis for a new manufacturing facility for glucose monitoring devices, adding several hundred jobs.

Roche will invest $50 billion over the next five years for new research and development sites across the US, including a new manufacturing facility in Indiana.

Roche said the investment would go toward high-tech research and development sites and new manufacturing facilities in places including Pennsylvania.

Roche said it will expand existing sites and construct new U.S. manufacturing and R&D infrastructure in areas such as gene therapy and cardiometabolic disease. The plans follow U.S. capital ...

Roche will invest $50 billion in U.S. manufacturing, including a new plant in Indiana. The Trump administration is considering tariffs on drugmakers.

Roche's trontinemab data showed dose-dependent amyloid reduction in Alzheimer's patients, while its Elecsys pTau181 test aims for European launch in 2025 ...